Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study

Giorlandino, Claudio; Cignini, Pietro; Padula, Francesco; Giannarelli, Diana; D’Emidio, Laura; Aloisi, Alessia; Plotti, Francesco; Angioli, Roberto

doi:10.1016/j.ajog.2014.10.003

Cited by 21 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…cardiac dysfunction, venous congestion, and delayed or abnormal lymphatic drainage), the real pathophysiological mechanism remains to be fully elucidated [19]. On the other hand, the effect of progesterone has been attempted to be explained by hemodynamic disturbance that leads to fluid accumulation [11]. Regardless, we are of the opinion that progesterone may also increase the NT by changing the ultra-structure of the extracellular matrix.…”

Section: Discussionmentioning

confidence: 97%

“…A recent study by Giorlandino et al [11], showed that exogenous progesterone therapy affects fetal NT thickness regardless of progesterone content, dosage, and route of administration. These authors had important confounders, including gestational age, maternal age, BMI, smoking status in their large numbered prospec- www.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, Giorlandino et al [11], speculated that exogenous progesterone use could lead to abnormal blood flow pattern, which in turn may affect fetal development in the first trimester. Also, they concluded that exogenous progesterone increases NT.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?

Kececioglu

Tokmak²,

Kececioglu³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

Objectives: The effect of exogenous progesterone on fetal nuchal translucency (NT) has been proposed recently. In this study, we aimed to compare the thickness of NT of patients receiving and not receiving progesterone for threatened miscarriage. Material and methods:This study was designed as a retrospective comparative study. Ninety five women treated with progesterone constituted the study group whereas 97 women who were not treated with progesterone constituted the control group. An ultrasonographic examination was performed on all of the women to measure NT. All patients were treated with oral micronized progesterone in the study group. The main parameters recorded for each woman were; age, body mass index (BMI), obstetrical characteristics, and gestational age at first examination, treatment duration of progesterone therapy, and results of combined and triple tests.Results: A total of 192 pregnant women with threatened miscarriage were included in this study. The mean NT thickness was statistically significantly higher in the study group (p < 0.001), and mean serum level of human chorionic gonadotropin (hCG) was also higher in this group (p < 0.05). There was no statistically significant difference between groups in terms of age, BMI, and gestational age at first examination. ROC curve analysis demonstrated that only increased NT (area under the curve: 0.634, p = 0.005, 95% CI: 0.541-0.727) was a discriminative factor for women receiving progesterone for threatened miscarriage. Also there was a positive correlation between NT and treatment duration (r = 0.269; p < 0.001). Conclusions:We think that oral progesterone therapy may increase NT depending on treatment duration without causing abnormal prenatal screening test results.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?

Kececioglu

Tokmak²,

Kececioglu³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

show abstract

“…Giorlandino et all. (2015) compared only NT between groups with 3582 patients and found that NT (MoM) in 11th weeks of gestation was higher in the progesteron group while NT in 12-14th weeks of gestation was similar between groups 12 . In the present study NT, serum PAPP-A and β-hCG levels and MoM values, which are markers of the first trimester screening test, did not change by using OMP.…”

Section: Discussionmentioning

confidence: 99%

“…Free β-hCG and PAPP-A are mostly released from placenta and progesterone can positively affect the placenta 12 , hence secretion of β-hCG and PAPP-A can be affected by exogenous progesterone. There are few investigations about effect of exogenous progesterone on PAPP-A and free β-hCG in the literature [12][13][14] . In the present study it was aimed to investigate whether or not NT thickness, maternal serum PAPP-A and free β-hCG levels can affected by the use of oral micronized progesterone (OMP) in first trimester pregnancies.…”

Section: Introductionmentioning

confidence: 99%

The effect of oral micronized progesterone on first trimester screening test markers and neonatal outcome

Madendağ¹,

Madendağ²,

Ak³

et al. 2019

Dicle Tıp Dergisi

View full text Add to dashboard Cite

Objective: It was aimed to investigate whether or not nuchal translucency(NT) thickness, maternal serum free betahuman chorionic gonadotropin(β-hCG) and pregnancy-associated plasma protein-A(PAPP-A) levels may affected by the use of oral micronized progesterone(OMP) in first trimester pregnancies. Also we aimed to evaluate pregnancy outcome in pregnant women using OMP. Method: This study was performed retrospectively including 1192 pregnant women, between January 2015 and August 2017. Body mass index(BMI), maternal and gestational age, levels of maternal serum PAPP-A and free β-hCG, NT measurement and the crown-rump length(CRL), fetal sex, fetal birth weight, Apgar score 5thminute<7 and admission to neonatal intensive care unit(NICU) were evaluated. Results: Maternal characteristics, ultrasound and biochemical parameters, fetal characteristics and neonatal outcome were evaluated. There was no statistically significant difference for maternal age, BMI, gestational age, PAPP-A, β-hCG, CRL, NT thickness, fetal sex, fetal birth weight, Apgar score 5th minute <7 and the number of admission to NICU during the first 28 days.

show abstract

A review of adverse events in animals and children after secondary exposure to transdermal hormone‐containing medicinal products

Sjöström

Mount

Klocker

et al. 2022

Veterinary Record Open

View full text Add to dashboard Cite

Background Hormonal replacement therapy is widely used to treat conditions in humans, the most well‐known indication being the relief of menopausal symptoms in women. Many of the hormone‐containing products (HCP) are applied to the skin. This transdermal delivery poses a risk to animals and humans through secondary exposure, especially when product information is not strictly followed. The aim of this article is to raise awareness among veterinarians and human healthcare providers of this risk; based on evidence from spontaneous reporting of suspected adverse events (AEs) in animals and humans. Interventions are also explored to mitigate the risk of secondary exposure to transdermal HCP (THCP). Review of spontaneously reported suspected AEs The Swedish Medical Products Agency has received several, mainly serious, AE reports in animals and children following secondary exposure to THCPs. The AE reports were reviewed together with worldwide data from the EudraVigilance Veterinary database and human EudraVigilance Data Analysis System. The clinical signs reported in animals included persistent signs of oestrus, poor growth rate and birth defects. In humans, reported clinical signs included precocious puberty, unresolved virilisation, accelerated growth rate and female infertility. Conclusions It is important that THCP are used according to manufacturer's instructions and users are made aware of risks and mitigating measures. This review of AEs in animals and children provides evidence to show that the use of THCP poses a risk for secondary exposure. Efficient communication strategies that stretch across veterinary and human medicinal disciplines are required to raise mutual awareness and minimise the risk of AEs in animals and humans.

show abstract

Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study

Cited by 21 publications

References 17 publications

Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?

Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?

The effect of oral micronized progesterone on first trimester screening test markers and neonatal outcome

A review of adverse events in animals and children after secondary exposure to transdermal hormone‐containing medicinal products

Contact Info

Product

Resources

About